[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Celltrion\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":106},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,4,0,[8,39,63,84],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":4,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":28,"lastUpdatePostDateStruct":29,"startDateStruct":32,"completionDateStruct":33,"leadSponsor":35,"locationsCount":38},"100589289","phase-3-a-study-to-compare-pharmacokinetics-efficacy-and-safety-of-subcutaneous-ct-p44-and-darzalex-faspro-in-combination-with-lenalidomide-and-dexamethasone-in-patients-with-refractory-or-relapsed-multiple-myeloma-100589289",false,"NCT06952478","A Study to Compare Pharmacokinetics, Efficacy and Safety of Subcutaneous CT-P44 and Darzalex Faspro in Combination With Lenalidomide and Dexamethasone in Patients With Refractory or Relapsed Multiple Myeloma","A Double-Blind, Randomized, Active-Controlled, Parallel-group, Phase 1\u002F3 Study to Compare Pharmacokinetics, Efficacy and Safety of Subcutaneous CT-P44 and Darzalex Faspro in Combination With Lenalidomide and Dexamethasone in Patients With Refractory or Relapsed Multiple Myeloma","\\[Main Inclusion Criteria\\]\n\n* Male or female with 18 years of age or older.\n* Patient must have documented multiple myeloma (MM) according to IMWG criteria\n* Patient must have a documented relapsed or refractory disease.\n* Patient must have achieved a response (PR or better based on investigator's determination of response by the IMWG criteria) to at least one prior regimen.\n* Patient must have a PD as defined by the IMWG criteria on or after their last line of therapy.\n\n\\[Main Exclusion Criteria\\]\n\n* Patient has received daratumumab or any other drug specifically targeting CD38 previously.\n* Patient's disease shows evidence of refractoriness or intolerance to lenalidomide.\n* Patient is known or suspected of not being able to comply with the study protocol (e.g., psychological disorder) or the patient has any condition for which, in the opinion of the investigator, participation would not be in the best interest of the patient (e.g., compromise their well-being) or that could prevent, limit, or confound the protocol-specified assessments.","ALL","18 Years",{"count":19,"type":20},486,"ESTIMATED","INTERVENTIONAL",[23],"PHASE3","This study is a phase 1\u002F3 study to Compare Pharmacokinetics, Efficacy and Safety of Subcutaneous CT-P44 and Darzalex Faspro in Combination with Lenalidomide and Dexamethasone in Patients with Refractory or Relapsed Multiple Myeloma",[26],"Refractory or Relapsed Multiple Myeloma","RECRUITING","2025-08-12",{"date":30,"type":31},"2025-08-15","ACTUAL",{"date":28,"type":31},{"date":34,"type":20},"2029-06-25",{"name":36,"class":37},"Celltrion","INDUSTRY",1,{"id":40,"slug":41,"hasResults":11,"nctId":42,"briefTitle":43,"officialTitle":44,"acronym":4,"eligibilityCriteria":45,"healthyVolunteers":11,"sex":16,"minAge":46,"maxAge":4,"enrollmentInfo":47,"targetDuration":4,"studyType":21,"phases":49,"briefSummary":50,"conditions":51,"keywords":4,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":55,"lastUpdatePostDateStruct":56,"startDateStruct":58,"completionDateStruct":60,"leadSponsor":62,"locationsCount":38},"100600129","phase-3-efficacy-and-safety-of-add-on-therapy-with-empagliflozin-in-patients-with-type-2-diabetes-on-a-background-of-alogliptin-and-metformin-100600129","NCT07093476","Efficacy and Safety of Add-On Therapy With Empagliflozin in Patients With Type 2 Diabetes on a Background of Alogliptin and Metformin","A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 3 Clinical Trial and Open-Label Extension Study to Evaluate the Efficacy and Safety of Add-On Therapy With Empagliflozin for Patients With Inadequately Controlled Type 2 DiabetesMellitus in the Combination Treatment With Metformin and Alogliptin","Inclusion Criteria:\n\n* Adults at the time of signing the Informed Consent Form (ICF)\n* Signed the written ICF voluntarily after being fully informed of the objectives, methods, and effects of the study\n* Diagnosed with T2DM\n\nExclusion Criteria:\n\n* Diagnosed with other types of diabetes than T2DM\n* History of hypersensitivity reaction to the components or drugs of the same class as the IP or the background therapy\n* Uncontrolled severe complications of diabetes","19 Years",{"count":48,"type":20},171,[23],"Phase 3 study to assess the Efficacy and Safety of CT-L02-301 in Type 2 Diabetes Patients with Insufficient Glycemic Control with Metformin and Alogliptin Combination Therapy.",[52,53,54],"T2DM","Diabete Type 2","DM","2025-08-07",{"date":57,"type":31},"2025-08-11",{"date":59,"type":31},"2025-07-18",{"date":61,"type":20},"2027-04",{"name":36,"class":37},{"id":64,"slug":65,"hasResults":11,"nctId":66,"briefTitle":67,"officialTitle":68,"acronym":4,"eligibilityCriteria":69,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":70,"targetDuration":4,"studyType":21,"phases":72,"briefSummary":73,"conditions":74,"keywords":4,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":76,"lastUpdatePostDateStruct":77,"startDateStruct":79,"completionDateStruct":81,"leadSponsor":83,"locationsCount":38},"100588299","phase-3-a-study-to-compare-effects-and-safety-of-ct-p51-and-keytruda-in-patients-with-previously-untreated-metastatic-lung-cancer-100588299","NCT06939595","A Study to Compare Effects and Safety of CT-P51 and Keytruda in Patients With Previously Untreated Metastatic Lung Cancer","A Double-Blind, Randomized, Active-Controlled, Parallel-Group, Phase 3 Study to Compare Efficacy and Safety of CT-P51 and Keytruda in Combination With Platinum-Pemetrexed Chemotherapy in Patients With Previously Untreated Metastatic Non-Squamous Non-Small Cell Lung Cancer","Inclusion Criteria:\n\n* Stage IV, non squamous NSCLC\n* Have not received any prior systemic anti-cancer therapy for metastatic NSCLC\n* Have at least 1 measurable lesion per RECIST version 1.1\n\nExclusion Criteria:\n\n* Have predominantly squamous cell histology NSCLC.\n* Hypersensitivity or contraindication to any component of the study drug, pemetrexed and cisplatin or carboplatin",{"count":71,"type":20},606,[23],"The goal of this Phase 3 clinical trial is to compare efficacy and safety of CT-P51 and European Union (EU) approved Keytruda in combination with platinum pemetrexed chemotherapy in patients with previously untreated metastatic nsNSCLC.",[75],"Non Squamous Non Small Cell Lung Cancer","2025-04-21",{"date":78,"type":31},"2025-04-23",{"date":80,"type":31},"2025-01-30",{"date":82,"type":20},"2028-07",{"name":36,"class":37},{"id":85,"slug":86,"hasResults":11,"nctId":87,"briefTitle":88,"officialTitle":89,"acronym":4,"eligibilityCriteria":90,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":91,"enrollmentInfo":92,"targetDuration":4,"studyType":21,"phases":94,"briefSummary":95,"conditions":96,"keywords":4,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":98,"lastUpdatePostDateStruct":99,"startDateStruct":101,"completionDateStruct":103,"leadSponsor":105,"locationsCount":38},"100508943","phase-3-a-study-to-compare-efficacy-pharmacokinetics-pharmacodynamics-and-safety-of-ct-p53-and-ocrevus-in-patients-with-relapsing-remitting-multiple-sclerosis-100508943","NCT05906992","A Study to Compare Efficacy, Pharmacokinetics, Pharmacodynamics and Safety of CT-P53 and Ocrevus in Patients With Relapsing-remitting Multiple Sclerosis","A Double-blind, Randomized, Active-controlled, Parallel Group, Phase 1\u002F3 Study to Compare Efficacy, Pharmacokinetics, Pharmacodynamics and Safety of CT-P53 and Ocrevus in Patients With Relapsing-remitting Multiple Sclerosis","Inclusion Criteria:\n\n* Patient diagnosed as multiple sclerosis (MS) in accordance with the revised McDonald criteria.\n* Patient has evidence of recent MS activity as defined in the study protocol\n* Patient has neurological stability for ≥30 days.\n* Patient with 0 to 6.0 (both inclusive) on the EDSS score.\n\nExclusion Criteria:\n\n* Patient diagnosed with primary or secondary progressive MS.\n* Patient diagnosed with MS for more than 15 years duration with an EDSS score ≤2.0 at Screening.\n* Patient unable to complete or has a contraindication to an MRI\n* Patient with contraindications and\u002For severe hypersensitivity to corticosteroids including methylprednisolone or any of the excipients of study drug or etcs defined in the study protocol.\n* Patient who has currently or history of any of medical conditions described in the study protocol.\n* Patients who have received or going to receive any of prohibited medications or treatments defined in the study protocol.","55 Years",{"count":93,"type":20},512,[23],"This is a double-blind, randomized, active-controlled, parallel group, Phase 1\u002F3 study to compare efficacy, PK, PD and overall safety of CT-P53 with Ocrevus in patients with Relapsing-remitting Multiple Sclerosis.",[97],"Relapsing-remitting Multiple Sclerosis","2024-05-20",{"date":100,"type":31},"2024-05-22",{"date":102,"type":31},"2024-01-11",{"date":104,"type":20},"2029-01",{"name":36,"class":37},""]